Phase 2 Data From The Ongoing HIBISCUS Study Shows Promise That Investigational Etavopivat Could Reduce The Incidence Of Vaso-Occlusive Crises In People With Sickle Cell Disease
Phase 2 Data From The Ongoing HIBISCUS Study Shows Promise That Investigational Etavopivat Could Reduce The Incidence Of Vaso-Occlusive Crises In People With Sickle Cell Disease . (MENAFN - PR Newswire) 
  
  
 
 
 
 
 
   
  Data indicated a trend toward reduced incidence of vaso-occlusive crises over 52 weeks and increased hemoglobin response at 24 weeks compared with ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108967029/Phase-2-Data-From-The-Ongoing-HIBISCUS-Study-Shows-Promise-That-Investigational-Etavopivat-Could-Reduce-The-Incidence-Of-Vaso-Occlusive-Crises-In-People-With-Sickle-Cell-Disease
2024-12-07
rss
(MENAFN - PR Newswire) 
  
  
 
 
 
 
 
   
  Data indicated a trend toward reduced incidence of vaso-occlusive crises over 52 weeks and increased hemoglobin response at 24 weeks compared with ...
Phase 2 Data From The Ongoing HIBISCUS Study Shows Promise That Investigational Etavopivat Could Reduce The Incidence Of Vaso-Occlusive Crises In People With Sickle Cell Disease